EASIX predicts non-relapse mortality after haploidentical transplantation with post-transplant cyclophosphamide

• DOI: 10.1038/s41409-022-01874-5
• Publication Date: 2022-11-22T23:05:07Z
• Authors: Jacopo Mariotti; Filippo Magri; Laura Giordano; Chiara De Philippis; Barbara Sarina; Daniele Mannina; Daniela Taurino; Armando Santoro; Stefania Bramanti
• Keywords: Leukemia, Myeloid, Acute; 03 medical and health sciences; Transplantation Conditioning; 0302 clinical medicine; Transplantation, Haploidentical; Hematopoietic Stem Cell Transplantation; Humans; Graft vs Host Disease; Neoplasm Recurrence, Local; Cyclophosphamide; Retrospective Studies

Endothelial Activation and Stress Index (EASIX) is a prognostic score reflecting endothelial damage. It can identify cohorts of patients at higher risk of non-relapse mortality (NRM) after allogeneic stem cell transplantation (SCT) from a matched-related or -unrelated donor. No data are available in the setting of haploidentical-SCT with post-transplant cyclophosphamide (PT-Cy). We retrospectively analyzed the role of EASIX score in a cohort of 266 patients receiving Haplo-SCT with PT-Cy at our center. By a decision-tree model, 1-year NRM was 16% vs. 29% and overall survival was 59% vs. 32%, respectively, for patients with a pre-transplant EASIX (EASIX-PRE) <0.8 vs. ≥0.8 (p < 0.001). By multivariable analysis, EASIX-PRE was an independent predictor of NRM (hazard ratio [HR] 2.43, p < 0.001) and overall survival (HR: 1.64, p = 0.011). EASIX-PRE did not predict patients at higher risk of developing acute graft-versus-host disease (GVHD) but was an independent predictor of 1-year NRM (3.2 cutoff, HR 6.61, p = 0.002; <3.2 vs. ≥3.2: 10% vs. 56%, p < 0.001) in patients developing acute GVHD. EASIX score can also represent an important tool to predict mortality in the setting of Haplo-SCT with PT-Cy. It may help to make therapeutic decisions both before the transplant and at the onset of acute GVHD.